Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NYSE:CYBN NASDAQ:FSTX NYSE:MBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$7.32-6.5%$8.64$56.35▼$105.00$212.17M0.9512,438 shs116,595 shsCYBNCybin$7.45-1.8%$7.98$4.81▼$13.88$175.75M0.68314,109 shs253,295 shsFSTXF-star Therapeutics$7.12$6.19$2.07▼$7.12$156.50M0.85709,213 shsN/AMBXMBX Biosciences$12.16+9.3%$12.19$4.81▼$27.50$406.44MN/A326,110 shs690,201 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-6.51%+1.81%-29.95%-15.38%-87.48%CYBNCybin-1.84%-1.46%-0.93%+5.67%+1,918.97%FSTXF-star Therapeutics0.00%0.00%0.00%0.00%0.00%MBXMBX Biosciences+9.25%-11.56%-8.43%+9.55%+1,215,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACYBNCybin2.845 of 5 stars3.60.00.00.03.20.81.3FSTXF-star TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.7047 of 5 stars3.50.00.00.03.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ACYBNCybin 3.25Buy$85.001,040.94% UpsideFSTXF-star Therapeutics 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.63209.42% UpsideCurrent Analyst Ratings BreakdownLatest FSTX, MBX, AVTE, and CYBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/8/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.005/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/AFSTXF-star Therapeutics$21.17M7.39N/AN/A$4.70 per share1.51MBXMBX BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)CYBNCybin-$57.88M-$3.88N/AN/AN/AN/A-37.58%-36.59%N/AFSTXF-star Therapeutics-$31.28M-$1.82N/AN/AN/AN/A-57.08%-42.40%N/AMBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest FSTX, MBX, AVTE, and CYBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AVTEAerovate Therapeutics-$0.25N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AFSTXF-star TherapeuticsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78CYBNCybinN/A24.2424.24FSTXF-star Therapeutics0.153.383.38MBXMBX BiosciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ACYBNCybin17.94%FSTXF-star Therapeutics31.50%MBXMBX BiosciencesN/AInsider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%CYBNCybin15.00%FSTXF-star Therapeutics3.20%MBXMBX Biosciences52.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCYBNCybin5023.59 million17.96 millionNot OptionableFSTXF-star Therapeutics8421.98 million21.28 millionNot OptionableMBXMBX Biosciences3633.42 millionN/AN/AFSTX, MBX, AVTE, and CYBN HeadlinesRecent News About These CompaniesMBX Biosciences (NYSE:MBX) Earns Outperform Rating from Analysts at MizuhoAugust 8 at 2:25 AM | americanbankingnews.comMBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 7 at 8:00 AM | globenewswire.comMBX Biosciences (NYSE:MBX) Coverage Initiated at MizuhoAugust 6 at 7:31 AM | marketbeat.comMizuho Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationAugust 5, 2025 | msn.comTD Asset Management Inc Raises Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)August 5, 2025 | marketbeat.comMBX Biosciences Inc. (MBX) Stock Price Today - WSJAugust 2, 2025 | wsj.comMBX Biosciences (NYSE:MBX) Shares Up 15.7% - What's Next?July 26, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Receives Average Rating of "Buy" from AnalystsJuly 19, 2025 | marketbeat.comOppenheimer Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationJuly 17, 2025 | msn.comOppenheimer Initiates Coverage on MBX Biosciences (NYSE:MBX)July 16, 2025 | marketbeat.comMBX Biosciences Inc Executives - MorningstarJune 25, 2025 | morningstar.comMMBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - MorningstarJune 24, 2025 | morningstar.comMMBX Biosciences Inc Chart - MorningstarJune 24, 2025 | morningstar.comMMBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical DevelopmentJune 23, 2025 | globenewswire.comMBX Biosciences Submits IND for Obesity TreatmentJune 16, 2025 | tipranks.comMBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of ObesityJune 16, 2025 | globenewswire.comMBX Biosciences to Present at the American Diabetes Association 85th Scientific SessionsJune 10, 2025 | globenewswire.commbx biosciences announces board changes and director electionsJune 7, 2025 | uk.investing.comMBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative BuyMay 31, 2025 | seekingalpha.comMBX Biosciences to Participate in June Investor ConferencesMay 20, 2025 | globenewswire.comMBX Biosciences, Inc.: Strong Buy Rating Amid Promising Phase II Data and Robust Financial PositionMay 13, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFSTX, MBX, AVTE, and CYBN Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$7.32 -0.51 (-6.51%) As of 08/7/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Cybin NYSE:CYBN$7.45 -0.14 (-1.84%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$7.48 +0.02 (+0.34%) As of 08/8/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.F-star Therapeutics NASDAQ:FSTXF-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.MBX Biosciences NYSE:MBX$12.16 +1.03 (+9.25%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$11.79 -0.37 (-3.03%) As of 08/8/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
